Clopidogrel hold time before neuraxial and pain procedures

There is no single number, and that is the answer. Three regional/interventional guidelines govern this depending on what you are about to do — and cardiology and surgical guidance add a fourth, shorter figure.

Published August 14, 2026 · Last reviewed September 27, 2026 · Written by Anastasia Jackson, DNAP, CRNA

Every clinical claim on this page is cited to its source below. How we source clinical content.

Why there is no single number

Clopidogrel is a prodrug requiring two metabolic steps to form the active compound, and its active metabolite binds the platelet P2Y12 receptor irreversibly.¹ That binding lasts for the life of the platelet, so recovery of function depends on producing new platelets rather than on clearing the drug. Platelet turnover is roughly 10–15% per day, which is where a five-to-seven-day interval comes from.

Several features of the drug make the interval less predictable than that arithmetic suggests:

• Maximum inhibition is only about 40–60% with a 75 mg maintenance dose, and platelet aggregation and bleeding time generally return toward baseline about 5 days after discontinuation, even though receptor blockade persists over the full platelet lifespan.¹⁴ Unlike aspirin, clopidogrel does not shut platelet function down completely, which is part of why shorter intervals have been argued for.
• Up to roughly 40% of patients respond poorly or not at all — so-called clopidogrel resistance, driven largely by insufficient generation of the active metabolite, by drug interactions, and by CYP2C19 genetic polymorphism.¹⁵ A meaningful fraction of patients holding the drug for a week were never well inhibited by it.
• Onset is slow. Time to peak effect can be as long as 24 hours with a maintenance dose, though a loading dose of 300–600 mg shortens that to 4–6 hours.¹ This is why the guidelines treat loading doses separately from maintenance doses at every decision point.
• Renal impairment further reduces predictability. Platelet inhibition is diminished in renal impairment, and reported spinal hematomas despite a 7-day hold have clustered in patients with renal impairment and traumatic procedures — a reason to favor the longer end of any interval in these patients.¹⁴

Neuraxial and peripheral blocks: 5–7 days

For spinal, epidural, deep plexus, and peripheral blocks, the ASRA Pain Medicine evidence-based guidelines, fifth edition, published January 2025, apply.²

Related P2Y12 agents in the same guideline: ticagrelor 5 days, and cangrelor 3 hours given its very short half-life.^2,3

On testing before a neuraxial block

ASRA notes that residual antiplatelet effect can be assessed with platelet function assays (for example, PFA II or a P2Y12 assay), but only a normalized value would be useful, and an acceptable level of residual antiplatelet effect remains undetermined. For a spinal or an epidural, its recommendation is the 5–7 day interval itself, with no testing alternative attached.²

Interventional spine and pain procedures: 7 days

A separate multi-society guideline governs interventional spine and pain work — a joint document from ASRA Pain Medicine, ESRA, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain.¹

It stratifies procedures as low, intermediate, or high bleeding risk, and recommends 7-day cessation of clopidogrel before spine or pain intervention. Spinal cord stimulator trial and implant sit in the high-risk category, on the reasoning that lead placement requires larger-gauge needles with a different bevel and stylet, and that multiple insertion attempts may be needed for adequate coverage — both of which increase potential trauma to vessels in the epidural space.⁶

The five-day option, stated precisely

The guideline also notes the disagreement it is arbitrating: ASRA and European regional anesthesia guidance have recommended a 7-day interval, while Scandinavian guidance held that 5 days is probably adequate, on the reasoning that new platelets form at 10–15% per day, leaving 50–75% of the circulating platelet pool unaffected 5 days after the drug is stopped.¹ That is a statement about the size of the unaffected pool, not a finding that clot formation is adequate at 5 days, and the guideline resolves the disagreement at 7 days.

A third number: ASIPP says 6 days

The American Society of Interventional Pain Physicians publishes its own guideline for interventional techniques, and it lands on a different figure again: clopidogrel and prasugrel discontinued for 6 days for high-risk and for intermediate or moderate-risk procedures, continued for low-risk procedures, with ticagrelor held 5 days for high-risk procedures.⁷ Two 2025 narrative reviews by the guideline’s lead author tabulate a shorter interval, 5 days for intermediate or moderate-risk procedures and 6 for high-risk, but they are secondary summaries and the guideline itself has not been amended.^17,18 This page follows the guideline.

ASIPP also builds risk stratification from patient factors rather than procedure alone, listing severe degenerative arthritis, spinal stenosis, ankylosing spondylitis, osteoporosis, older age, frailty, prior stroke or intracranial bleed, hypertension, diabetes, thrombocytopenia, chronic renal failure, chronic NSAID or steroid therapy, multiple needle attempts, epidural fibrosis, and previous surgery as reasons to upgrade a procedure’s risk category.⁷

A fourth number: cardiology and surgery say 5 days

Outside the regional and interventional-pain world, the mainstream perioperative guidance for non-neuraxial surgery lands shorter still. Both the American College of Chest Physicians 2022 perioperative guideline and the 2026 American College of Cardiology scientific statement recommend stopping clopidogrel 5 days before an operation.^12,13

This matters for two reasons. It shows the shorter interval is not a Scandinavian outlier but the position of mainstream cardiology and surgical bodies, and it is the reason a treating cardiologist and a proceduralist often start from different numbers when they discuss the same patient. It does not, however, license a 5-day interval before a spinal or an SCS: those procedures are governed by the neuraxial and interventional guidelines above, whose bleeding-risk calculus is different from that of general surgery.

Where that leaves you

Restarting — where the guidelines diverge again

This is the half of the question most often left out, and the two documents do not agree here either.

The dissent worth knowing about

The interventional pain community has not accepted the 7-day recommendation uniformly, and the disagreement is published rather than informal.

The Spine Intervention Society’s Patient Safety Committee, writing in its FactFinders series, notes that the guidelines recommend discontinuing clopidogrel before all intermediate-risk spinal interventions regardless of thrombotic risk, and states plainly that this recommendation may not be consistent with the facts derived from the available published evidence.⁹ Their position is that the decision to withhold antiplatelet therapy before a lumbar transforaminal epidural steroid injection should be made case by case.

Supporting observational data exist. A prospective series reported 278 cervical epidural injections performed on clopidogrel, warfarin, or aspirin, alone or in combination, without clinical epidural hematoma; a separate retrospective series of 240 cervical or thoracic interlaminar epidural injections in patients on anticoagulant or antiplatelet medication reported no symptomatic epidural hematomas.¹⁰

The other half of the decision: the risk of stopping

Every hold interval on this page is a bleeding-risk recommendation. None of them accounts for why the patient is taking the drug.

ASIPP states the trade-off directly: the risk of thromboembolic events and their associated morbidity and mortality is higher than the risk of epidural hematoma formation and its associated morbidity with prompt management — while noting that both risks are significant.⁷

Practically, that means the following patients deserve a conversation with the prescriber before the drug is held at all:

• Recent coronary stent — particularly within the first months after placement, where interruption of dual antiplatelet therapy carries stent thrombosis risk.
• Recent stroke or TIA on clopidogrel for secondary prevention.
• Peripheral arterial disease with prior revascularization.
• Any patient for whom an elective procedure is being scheduled around the hold — in which case the question is whether the procedure is worth the interruption, not how long the interruption should be.

Shared decision-making between the patient, the proceduralist, and the treating physicians is recommended whenever cessation is being contemplated.⁷ That recommendation exists because the person who prescribed the clopidogrel usually knows something the proceduralist does not.

The practical reading

• Spinal or epidural? Use the interval — 5–7 days. Testing is not an established substitute.
• Spinal cord stimulator or interventional pain procedure? Seven days is the recommendation. Five days with documented platelet function recovery is a named alternative, but it belongs to the situation where the cardiologist has set that interval, not to convenience.
• Expect cardiology to quote 5 days. That is correct for general surgery under ACCP and ACC guidance; it does not override the 7-day neuraxial/interventional numbers.
• Continue low-dose aspirin unless there is a specific reason not to — it is the P2Y12 agent that drives the hold.
• Lengthen the interval in renal impairment, where platelet inhibition is less predictable and hematomas despite a nominal hold have been reported.
• Check which guideline your institution has adopted. Several societies publish several intervals, and the number in your protocol came from one of them.
• Do not forget the restart. It differs between the two documents, and it is the part most likely to be omitted from a discharge order.
• Ask why the patient is on it before deciding how long to stop it.
• The interval often settles the anesthetic before anything else does. In the older hip fracture patient it decides spinal versus general on its own — which matters less than it sounds, because the randomized trials found neither technique superior, so there is little reason to delay surgery to make a spinal possible.

Frequently asked questions

How long should clopidogrel be held before a spinal or epidural?

Five to seven days. The ASRA Pain Medicine evidence-based guidelines, fifth edition (2025), give a suggested interval of 5–7 days between discontinuing clopidogrel and needle placement, graded IIC.²

Can a platelet function test replace the hold time before a neuraxial block?

No. ASRA notes that residual antiplatelet effect can be assessed with platelet function assays, but only a normalized value would be useful, and an acceptable level of residual antiplatelet effect remains undetermined; its recommendation is the 5–7 day interval, with no testing alternative attached.² Notably, the fifth edition did introduce drug-level thresholds for direct oral anticoagulants — so the absence of a testing pathway for antiplatelet agents reflects a considered position rather than an outdated one.^2,5

Why do some sources say 7 days and others say 5?

Because they govern different procedures — and different specialties weigh bleeding risk differently. The 5–7 day figure comes from the regional anesthesia guideline covering neuraxial and peripheral blocks. The 7-day figure comes from a separate multi-society guideline covering interventional spine and pain procedures.^1,2 A third society, ASIPP, recommends 6 days for high and intermediate risk interventional techniques.⁷ Cardiology and surgical guidance — the 2022 ACCP guideline and the 2026 ACC statement — recommend 5 days before general surgery.^12,13 The underlying disagreement is longstanding — Scandinavian guidance has held that 5 days is probably adequate, while ASRA and European regional anesthesia guidance recommended 7.¹

When can clopidogrel be given at five days with platelet function testing?

The provision is narrower than it is usually described. The multi-society guideline recommends 7-day cessation, and states that if five days is what the managing cardiologist or vascular medicine physician recommends — specifically before an extended spinal cord stimulator trial — then a test of platelet function should be performed.¹ The shortened interval is driven by the patient’s thrombotic risk as judged by the physician managing it; the platelet test is the check placed on that decision.

When should clopidogrel be restarted after a block or injection?

The two guidelines differ. ASRA states that thienopyridine therapy may be resumed immediately after needle placement or catheter removal, provided a loading dose is not administered, and suggests a 6-hour interval between catheter removal and a loading dose.² The interventional pain guideline states that the usual 75 mg daily dose may be started 12 hours after the procedure, with a 24-hour interval if a loading dose is used.⁸

Can an epidural catheter be maintained on clopidogrel?

For 1–2 days, provided a loading dose is not administered — because the antiplatelet effect of clopidogrel is not immediate. Catheters should not be maintained on prasugrel or ticagrelor because of their rapid onset.²

Is it ever reasonable to proceed without holding clopidogrel?

For low-risk interventional techniques, ASIPP recommends continuation rather than cessation.⁷ The Spine Intervention Society has argued that the decision to withhold antiplatelet therapy before lumbar transforaminal epidural steroid injections should be made case by case rather than by universal policy.⁹ For neuraxial anesthesia, no guideline currently supports proceeding on a therapeutic antiplatelet agent, and the decision to do so in an urgent situation is an institutional and individual risk judgment rather than a guideline-supported one.

References

1. Narouze S, Benzon HT, Provenzano D, Buvanendran A, De Andres J, Deer T, Rauck R, Huntoon MA. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications (second edition): guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2018;43(3):225–262. doi:10.1097/AAP.0000000000000700. PMID 29278603
2. Kopp SL, Vandermeulen E, McBane RD, Perlas A, Leffert L, Horlocker T. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition). Reg Anesth Pain Med. Published online 29 January 2025. doi:10.1136/rapm-2024-105766. PMID 39880411
3. ASRA Guidelines for Regional Anesthesia with Antithrombotic or Thrombolytic Therapy, 5th edition — guideline summary. Guideline Central, summarizing the guideline at reference 2. guidelinecentral.com/guideline/4293939. Tabulates the P2Y12 intervals and recommendation grades quoted above.
4. Updated guidance on anesthesia with antithrombotic/thrombolytic therapy. Medscape, 7 February 2025. medscape.com/viewarticle/updated-guidance-anesthesia-antithrombotic-thrombolytic-2025a1000339. Media briefing remarks by lead author Sandra Kopp, MD, describing the two principal changes in the fifth edition.
5. The drug-level thresholds for apixaban, rivaroxaban and edoxaban, and for low molecular weight heparin, are from the fifth-edition guideline itself at reference 2.
6. ASRA Pain Medicine anticoagulation problem-based learning discussion: regional anesthesia and pain procedures in anticoagulated patients. ASRA Pain Medicine, 1 September 2025. asra.com/news-publications/asra-updates/blog-landing/legacy-b-blog-posts/2025/09/01/asra-pain-medicine-anticoagulation-pbld---regional-anesthesia-and-pain-procedures-in-anticoagulated-patients. Describes the rationale for classifying SCS trial and implant as high risk.
7. Perioperative management of antiplatelet and anticoagulant therapy in patients undergoing interventional techniques: 2024 updated guidelines from the American Society of Interventional Pain Physicians (ASIPP). Pain Physician. 2024;27(S6):S1–S94. doi:10.36076/ppj.2024.7.s1.
8. Updates to the ASRA guidelines for interventional pain procedures. ASRA News, 27 August 2019. asra.com/news-publications/asra-newsletter/newsletter-item/asra-news/2019/08/27/updates-to-the-asra-guidelines-for-interventional-pain-procedures. Summarizing restart intervals from the second-edition interventional guideline.
9. FactFinders for patient safety: antithrombotics and interventional pain procedures — lumbar transforaminal epidural steroid injections and lumbar medial branch radiofrequency neurotomy. Spine Intervention Society Patient Safety Committee. Interv Pain Med. 2022. PMC11411602
10. Safety profile of cervical transforaminal epidural steroid injections performed while maintaining anticoagulation, aspirin, or NSAIDs. Interv Pain Med. 2025. PMC12486170. Summarizing prior series by Furman and colleagues and a prospective series of cervical epidural injections on clopidogrel, warfarin, or aspirin.
11. Kopp SL, et al., fifth edition, as at reference 2. Reg Anesth Pain Med. Published online 29 January 2025. doi:10.1136/rapm-2024-105766. PMID 39880411. On the methodological limits of the evidence base — the rarity of spinal hematoma precludes a prospective randomized study and no laboratory model exists.
12. Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest. 2022;162(5):e207–e243. Recommends stopping clopidogrel approximately 5 days before surgery.
13. Kumbhani DJ, Gibson CM, Kinlay S, et al. Antiplatelet therapy in the management of atherosclerotic cardiovascular disease: 2026 ACC scientific statement: a report of the American College of Cardiology. J Am Coll Cardiol. 2026. Recommends discontinuing clopidogrel 5 days before surgery.
14. Plavix (clopidogrel) prescribing information. Food and Drug Administration, 2025. Steady-state inhibition of platelet aggregation of approximately 40–60% with 75 mg daily; platelet aggregation and bleeding time return toward baseline generally about 5 days after discontinuation; reduced platelet inhibition in renal impairment.
15. Schilling U, Dingemanse J, Ufer M. Pharmacokinetics and pharmacodynamics of approved and investigational P2Y12 receptor antagonists. Clin Pharmacokinet. 2020;59(5):545–566. Up to approximately 40% of patients respond poorly to clopidogrel, largely from insufficient active-metabolite generation, drug interactions, and CYP2C19 polymorphism.
16. Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest. 2022;162(5):e207–e243; and Keeling D, Tait RC, Watson H. Peri-operative management of anticoagulation and antiplatelet therapy. Br J Haematol. 2016;175(4):602–613. Low-dose aspirin is generally continued through neuraxial and interventional procedures.
17. Manchikanti L, Kaye AD, Nampiaparampil DE, et al. Perioperative management of patients receiving interventional techniques and antiplatelet and anticoagulant therapy: a balancing act. Curr Pain Headache Rep. 2025;29(1):107. doi:10.1007/s11916-025-01405-z. Narrative review; tabulates clopidogrel and prasugrel at 5 days for intermediate/moderate risk and 6 days for high risk.
18. Manchikanti L, Abd-Elsayed A, Kaye AD, et al. Review of guidelines for implantable peripheral nerve stimulation (PNS) in the management of chronic pain. Curr Pain Headache Rep. 2025;29(1):89. doi:10.1007/s11916-025-01397-w. Carries the same 5-day intermediate-risk table.